Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.
about
Identification of novel functional inhibitors of acid sphingomyelinaseEvolving concepts in cancer therapy through targeting sphingolipid metabolismExtracellular Vesicles in Multiple Sclerosis: What are They Telling Us?Fingolimod for the treatment of neurological diseases-state of play and future perspectivesEngineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioningEvidence for coordination of lysosomal (ASMase) and plasma membrane (NSMase2) forms of sphingomyelinase from mutant mice.Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.Sphingosine 1-phosphate signalling in cancer.Microvesicles: What is the Role in Multiple Sclerosis?Inhibition of P2X7 receptors improves outcomes after traumatic brain injury in rats.Quantum dot-mediated delivery of siRNA to inhibit sphingomyelinase activities in brain-derived cells.Sphingosine-1-phosphate modulators in inflammatory skin diseases - lining up for clinical translation.Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects.Selectivity and specificity of sphingosine 1-phosphate receptor ligands: "off-targets" or complex pharmacology?Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents.Myeloid microvesicles are a marker and therapeutic target for neuroinflammation.Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.Topical Application of Fingolimod Perturbs Cutaneous Inflammation.New Insights Into Immune Cell-Derived Extracellular Vesicles in Multiple Sclerosis
P2860
Q21003953-96E548C3-1AE4-40C6-B671-DDF2F92EBFBEQ26863646-E2781C8F-0641-45A6-A2BC-CA71B134956BQ27022494-897EC19A-EE73-40A5-A7F9-0DBBDC78F225Q27026175-8709BAEB-A304-422C-9725-C00F02C97E69Q30370009-A2BD1074-1C2D-426A-AC0C-4B0C52F157B3Q36401748-27E28D80-67C1-463C-993B-400BF2B43739Q37880161-CD1DC02E-028F-4C32-9784-C7615D1775E2Q37977171-AB11233E-C265-41C4-8E4D-D92453A9E7C8Q38527788-209AEC9C-9186-4233-822D-A277F883258CQ38617347-9716F887-19CE-429B-BBC9-5CAEABE68AC7Q38746607-15913CA9-6E43-4FEE-BAE9-F2E8FBD9ED68Q38940670-64B23DEF-D132-4E5E-8BEB-D6E5BF2518DCQ42127017-4E712586-A5D9-4AD2-912E-2E6A8EC5C716Q42742032-1401C58F-74BC-4A31-9974-F3B4CBC9D166Q46426783-703B6449-6A70-497E-9B40-6CFD9A4EF548Q48316352-50D19D54-B36D-4FC7-8BAB-095EA1CD875FQ48435795-B8EE2460-E917-4923-AF61-06D485DE4AE6Q53142659-25D434CD-E833-4B82-8848-544DA9301EB0Q58785905-89D57DB1-722C-4273-9BE5-F574E9F429D7
P2860
Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Gilenya (FTY720) inhibits acid ...... to tricyclic antidepressants.
@en
Gilenya
@nl
type
label
Gilenya (FTY720) inhibits acid ...... to tricyclic antidepressants.
@en
Gilenya
@nl
prefLabel
Gilenya (FTY720) inhibits acid ...... to tricyclic antidepressants.
@en
Gilenya
@nl
P2860
P1476
Gilenya (FTY720) inhibits acid ...... to tricyclic antidepressants.
@en
P2093
Glyn Dawson
Jingdong Qin
P2860
P304
P356
10.1016/J.BBRC.2010.11.115
P407
P577
2010-12-03T00:00:00Z